Methods Of Treating Kidney Stones
In one aspect, a method of treating or preventing kidney stones in a patient is provided. A therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate or hydrate thereof which induces glucosuria or a pharmaceutical composition thereof is administered to the patient in need thereof.
1 . A method of treating or preventing kidney stones in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, solvate or hydrate thereof which induces glucosuria or a pharmaceutical composition thereof.
2 . The method of claim 1 , wherein the kidney stone is a calcium stone.
3 . The method of claim 1 , wherein the kidney stone is a cystine stone.
4 . The method of claim 1 , wherein the kidney stone is a struvite stone.
5 . The method of claim 1 , wherein the kidney stone is uric acid stone.
6 . The method of claim 1 wherein the compound is an SGLT-2 inhibitor.
7 . The method of claim 6 , wherein the SGLT-2 inhibitor is Empagliflozin, Ipragliflozin, Tofogliflozin, Canagliflozin, Lueseogliflozin, Ertugliflozin, Dapagliflozin, Remogliflozin, Sotagliflozin, Sergliflozin, Canagliflozin/metformin, Dapagliflozin/metformin, Empagliflozin/metformin, Empagliflozin/linagliptin, Ertugliflozin/metformin, Ertugliflozin/sitagliptin, Ipragliflozin/sitagliptin, Canagliflozin/teneligliptin or Dapagliflozin/saxagliptin.
8 . The method of claim 3 further comprising co-administering a compound or a pharmaceutically acceptable salt, solvate or hydrate thereof with a sulfhydryl group or a disulfide group.
9 . The method of claim 8 , wherein the compound is captopril, tiopronin or D-pencillamin.
10 . The method of claim 1 further comprising co-administering an acid anion.
11 . The method of claim 10 , wherein the acid anion is citrate anion.
12 . The method of claim 11 , wherein the citrate anion is potassium citrate.
13 . The method of claim 6 , wherein the therapeutically effective amount of the SGLT-2 inhibitor is between about 20% inhibition of SCL-2 and about 80% inhibition of SCL-2.
14 . The method of claim 1 , wherein the cumulative excretion of glucose (g/day) in the urine over between a 0 and a 20 h period is between about 5 gm and about 60 gm.
15 . A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt, solvate or hydrate thereof which induces glucosuria, an acid salt and a pharmaceutically acceptable vehicle.
16 . The pharmaceutical composition of claim 15 , wherein the vehicle includes a compound or a pharmaceutically acceptable, solvate or hydrate thereof with a sulfhydryl or disulfide group.
17 . The pharmaceutical composition of claim 15 wherein the vehicle is a solid.
18 . The pharmaceutical composition of claim 17 , wherein the solid comprises a pill or tablet.
19 . The pharmaceutical composition of claim 18 , wherein the acid salt is potassium citrate.
20 . The pharmaceutical composition of claim 16 , wherein the ratio of acid salt to the compound is between about 5 mEq and about 60 mEq.